Skip to main content

Table 1 Characteristics of cases hospitalised with Campylobacter bacteraemia, 2004 to 2013

From: Bacteraemia, antimicrobial susceptibility and treatment among Campylobacter-associated hospitalisations in the Australian Capital Territory: a review

Year (case)

Age range/sex

Species

Bacteraemia—source

Antimicrobial susceptibility

Antimicrobial treatment

Significant medical history and risk factors

2004

80 + M

C. jejuni

Enteric—secondary

Fully sensitive

Nil

Age, nil other significant

2005 (a)

50–59 F

Campylobacter sp.

Enteric—secondary

Fully sensitive

PO ciprofloxacin 500 mg bd

Acute myeloid leukaemia

2005 (b)

60–69 F

Campylobacter sp.

Enteric—secondary

Fully sensitive

Nil

Nil significant

2005 (c)

40–49 F

C. jejuni

Enteric—secondary

Fully sensitive

PO ciprofloxacin 500 mg bd

IV drug use, PUD on omeprazole

2006 (a)

40–49 M

C. jejuni

Enteric— secondary

Fully sensitive

PO ciprofloxacin 500 mg bd

Untreated Stage III HIV

2008 (a)

20–29 M

Campylobacter sp.

Enteric—secondary

Fully sensitive

IV azithromycin 500 mg qd

Nil significant

2008 (b)

60–69 M

C. coli

Primary bacteraemia

Ciprofloxacin- Resistant

Erythromycin- Resistant

Nil

Lymphocytic lymphoma

2009

30–39 F

C. jejuni

Enteric—secondary

Fully sensitive

PO ciprofloxacin 250 mg bd

History of renal transplant secondary to IgA nephropathy

2010 (a)

60–69 M

Campylobacter sp.

Enteric—secondary

Fully sensitive

PO ciprofloxacin 500 mg bd

Bowel carcinoma, current chemotherapy

2010 (b)

30–39 M

C. coli

Enteric—secondary

Fully sensitive

PO ciprofloxacin 500 mg bd

Alcoholic liver disease with portal hypotension and bleeding varices

2010 (c)

70–79 F

C. jejuni

Enteric—secondary

Fully sensitive

PO ciprofloxacin 500 mg bd

T2DM

2010 (d)

10–19 F

C. jejuni

Enteric—secondary

Fully sensitive

PO azithromycin 500 mg qd (upon discharge)

Nil significant.

2010 (e)

70–79 F

C. coli

Enteric—secondary

Fully sensitive

PO ciprofloxacin 500 mg bd

T2DM

2010 (f)

40–49 M

C. jejuni

Enteric—secondary

Fully sensitive

PO Norfloxacin 400 mg bd

Irritable bowel syndrome

2011 (a)

60–69 M

C. lari

Enteric—secondary

Ciprofloxacin— Resistant

PO Doxycycline 100 mg bd

Alcoholic liver disease with portal hypotension, recent intracerebral bleed

2011 (b)

80 + M

C. jejuni

Enteric—secondary

Fully sensitive

Nil prescribed

Age, nil other significant

2011 (c)

70–79 M

C. coli

Enteric—secondary

Fully sensitive

PO ciprofloxacin 500 mg bd

Asplenic

2012 (a)

40–49 M

C. jejuni

Enteric—secondary

Fully sensitive

IV ciprofloxacin 500 mg bd

Multiple sclerosis, current chemotherapy pre-stem cell transplantation, IDDM

2012 (b)

30–39 F

C. jejuni

Enteric—secondary

Fully sensitive

Nil

Pregnant 33/40K, IDDM

2012 (c)

70–79 M

C. jejuni

Enteric—secondary

Ciprofloxacin— Resistant

Nalidixic acid— Resistant

Nil

Diabetic neuropathy, chronic renal failure

2012 (d)

60–69 F

C. coli

Enteric—secondary

Ciprofloxacin— Resistant

Nalidixic acid— Resistant

Nil

Nil significant

2013 (a)

20–29 M

C. jejuni

Enteric—secondary

Fully sensitive

Nil

Nil significant

2013 (b)

20–29 M

C. jejuni

Primary bacteraemia

Fully sensitive

PO Ciprofloxacin 750 mg bd (upon discharge)

B cell leukaemia, AVN (on steroids), SIADH

2013 (c)

50–59 M

C. jejuni

Enteric—secondary

Fully sensitive

PO ciprofloxacin 500 mg bd

Liver failure with cirrhosis, portal hypotension secondary to Hepatitis C, T2DM, hypothyroidism. Awaiting transplant.

2013 (d)

70–79 M

C. jejuni

Enteric—secondary

Fully sensitive

Nil

Age, nil other significant

  1. PO, per oral; IV ,  intravenous; PUD, peptic ulcer disease; HIV, human immunodeficiency virus; T2DM, type 2 diabetes mellitus; IDDM, insulin dependent diabetes mellitus; AVN, acute vascular necrosis; SIADH, syndrome of inappropriate antidiuretic hormone